Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate.

MLA

Singh, Shweta, et al. “Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate.” Molecular Cancer Therapeutics, vol. 21, no. 8, Aug. 2022, pp. 1326–36. EBSCOhost, https://doi.org/10.1158/1535-7163.MCT-21-0193.

APA

Singh, S., Serwer, L., DuPage, A., Elkins, K., Chauhan, N., Ravn, M., Buchanan, F., Wang, L., Krimm, M., Wong, K., Sagert, J., Tipton, K., Moore, S. J., Huang, Y., Jang, A., Ureno, E., Miller, A., Patrick, S., Duvur, S., … Richardson, J. (2022). Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate. Molecular Cancer Therapeutics, 21(8), 1326–1336. https://doi.org/10.1158/1535-7163.MCT-21-0193

Chicago

Singh, Shweta, Laura Serwer, Amy DuPage, Kristi Elkins, Niharika Chauhan, Matthew Ravn, Fritz Buchanan, et al. 2022. “Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate.” Molecular Cancer Therapeutics 21 (8): 1326–36. doi:10.1158/1535-7163.MCT-21-0193.